Innocan Pharma Corporation announced the results of a recent study showed the presence of Cannabidiol (CBD) in mice's brains, 41 days after being injected with company's CBD LPT (CBD-Loaded Liposome Platform Technology). In contrast, no CBD was demonstrated in mice's brains, 22 days following the injection of free CBD (without using company's LPT delivery system). Prolonged and controlled release of CBD from company's novel Delivery System injected subcutaneously, showed continuous clinically relevant concentrations of CBD in the blood for a long time. The Company believes this will be a good predictor of CBD exposure when administered in humans. The Company believes that the continuous and long blood presence of CBD in blood for a longer time post local administration, seems to be superior to orally administered CBD in two aspects: it will all allow a single administration of CBD instead of daily administration; and it will overcome the low (10% - 20%) oral bioavailability of CBD. The superior PK of the CBD Delivery System administered, may achieve controlled concentration of CBD in the blood leading to a better clinical outcome.